Zentalis Q1 net loss narrows as operating expenses fall

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals

ZNTL

0.00


Overview

  • US oncology drug developer's Q1 net loss narrowed yr/yr as operating expenses declined

  • Company advanced azenosertib pivotal and confirmatory trials for Cyclin E1-positive ovarian cancer

  • Cash position was $211.8 mln at March 31, 2026, providing runway into late 2027


Outlook

  • Company expects DENALI Phase 2 topline readout by year-end 2026

  • ASPENOVA Phase 3 trial initiated to support full approval and ex-US registrations

  • Company says cash position expected to fund operations into late 2027


Result Drivers

  • CLINICAL TRIAL ADVANCEMENT - Higher R&D expenses in Q1 driven by increased clinical and manufacturing costs related to DENALI and ASPENOVA trials

  • OPERATING EXPENSE DECREASE - Total operating expenses fell yr/yr due to non-recurring restructuring charge in Q1 2025

  • PRE-COMMERCIAL PREPARATION - Co initiated pre-commercial launch activities, including scaling manufacturing and advancing companion diagnostic market development


Company press release: ID:nGNX5MmTmY


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$0.50


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 28.5% above its May 12 closing price of $4.28


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.